Antibiotic treatment of male urinary tract infections: scientific rationale behind the 2026 SPILF guidelines
Abstract
The management of male urinary tract infections (UTIs) has historically been based on a monolithic approach, under which every episode was treated as acute prostatitis, leading to prolonged antibiotic courses. To address rising bacterial resistance and promote antimicrobial stewardship, the French Infectious Diseases Society (SPILF) updated its guidelines in 2026, introducing a stratified management framework. This review outlines the scientific evidence underlying these updated recommendations. A comprehensive review of recent literature, including randomized controlled trials and large-scale retrospective cohorts, was conducted so as to evaluate antibiotic efficacy, resistance patterns, and optimal treatment durations for male cystitis, febrile UTIs (prostatitis/pyelonephritis), and acute epididymo-orchitis. Evidence validates distinguishing male cystitis from febrile UTI. For male cystitis, 7-day regimens using narrow-spectrum oral agents-such as fosfomycin trometamol, nitrofurantoin, or pivmecillinam-achieve satisfactory clinical success with minimal risk of complications. Conversely, febrile UTIs require initial parenteral third-generation cephalosporins or oral fluoroquinolones. For targeted oral step-down therapy in prostatitis, cotrimoxazole is preferred over fluoroquinolones so as to minimize ecological impact, while amoxicillin remains the drug of choice for enterococcal coverage. Although recent data show that seven days can be sufficient for selected bacteremic presentations, to prevent relapses a conventional 14-day duration remains the standard for acute prostatitis. Non-sexually transmitted orchitis and epididymitis require a 10-day course of fluoroquinolones or cotrimoxazole. The 2026 SPILF guidelines represent a paradigm shift toward a tailored, stratified approach.
Related
- Antimicrobial practices for Mycoplasma infections in cattle: A survey of veterinary practitioners in light of current scientific evidence and national guidelines
- Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia
- ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
- Scientific criteria and guidelines for identifying, reporting and interpreting omics data – transcriptomics, proteomics, metabolomics and lipidomics – in meat science research
- A European perspective on antibiotic use in viral respiratory infections: new paradigm integrating pathogens with host factors
BibTeX
@article{forestier2026antibiotic,
title = {{Antibiotic treatment of male urinary tract infections: scientific rationale behind the 2026 SPILF guidelines}},
author = {Emmanuel Forestier and Benjamin Soudais and Yvan Caspar and Manuel Etienne and Hélène Milacic and Véronique Orcel and Claire Roubaud-Baudron and Maxime Vallée and Aurélien Dinh and Matthieu Lafaurie},
journal = {Infectious Diseases Now},
year = {2026},
month = sep,
doi = {10.1016/j.idnow.2026.105319},
url = {https://hal.science/hal-05734681v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antibiotic treatment of male urinary tract infections: scientific rationale behind the 2026 SPILF guidelines
AU - Emmanuel Forestier
AU - Benjamin Soudais
AU - Yvan Caspar
AU - Manuel Etienne
AU - Hélène Milacic
AU - Véronique Orcel
AU - Claire Roubaud-Baudron
AU - Maxime Vallée
AU - Aurélien Dinh
AU - Matthieu Lafaurie
PY - 2026
DA - 2026/09/01
JO - Infectious Diseases Now
DO - 10.1016/j.idnow.2026.105319
UR - https://hal.science/hal-05734681v1
AB - The management of male urinary tract infections (UTIs) has historically been based on a monolithic approach, under which every episode was treated as acute prostatitis, leading to prolonged antibiotic courses. To address rising bacterial resistance and promote antimicrobial stewardship, the French Infectious Diseases Society (SPILF) updated its guidelines in 2026, introducing a stratified management framework. This review outlines the scientific evidence underlying these updated recommendations. A comprehensive review of recent literature, including randomized controlled trials and large-scale retrospective cohorts, was conducted so as to evaluate antibiotic efficacy, resistance patterns, and optimal treatment durations for male cystitis, febrile UTIs (prostatitis/pyelonephritis), and acute epididymo-orchitis. Evidence validates distinguishing male cystitis from febrile UTI. For male cystitis, 7-day regimens using narrow-spectrum oral agents-such as fosfomycin trometamol, nitrofurantoin, or pivmecillinam-achieve satisfactory clinical success with minimal risk of complications. Conversely, febrile UTIs require initial parenteral third-generation cephalosporins or oral fluoroquinolones. For targeted oral step-down therapy in prostatitis, cotrimoxazole is preferred over fluoroquinolones so as to minimize ecological impact, while amoxicillin remains the drug of choice for enterococcal coverage. Although recent data show that seven days can be sufficient for selected bacteremic presentations, to prevent relapses a conventional 14-day duration remains the standard for acute prostatitis. Non-sexually transmitted orchitis and epididymitis require a 10-day course of fluoroquinolones or cotrimoxazole. The 2026 SPILF guidelines represent a paradigm shift toward a tailored, stratified approach.
SN - 2666-9927
SN - 2666-9919
ER -